KCM
Kynam Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $79.8M | Hold |
8,520,000
| – | – | 8.59% | 4 |
|
|
2025
Q1 | $105M | Hold |
8,520,000
| – | – | 8.79% | 4 |
|
|
2024
Q4 | $113M | Buy |
8,520,000
+2,677,075
| +46% | +$35.4M | 6.66% | 4 |
|
|
2024
Q3 | $112M | Buy |
5,842,925
+120,868
| +2% | +$2.33M | 8.62% | 4 |
|
|
2024
Q2 | $117M | Buy |
5,722,057
+62,057
| +1% | +$1.27M | 9.06% | 3 |
|
|
2024
Q1 | $135M | Hold |
5,660,000
| – | – | 14.1% | 2 |
|
|
2023
Q4 | $122M | Buy |
5,660,000
+2,060,000
| +57% | +$44.5M | 13.55% | 2 |
|
|
2023
Q3 | $52.3M | Buy |
3,600,000
+337,996
| +10% | +$4.91M | 8.55% | 4 |
|
|
2023
Q2 | $68.3M | Buy |
3,262,004
+56,018
| +2% | +$1.17M | 9.39% | 3 |
|
|
2023
Q1 | $67.7M | Buy |
3,205,986
+644,799
| +25% | +$13.6M | 8.74% | 3 |
|
|
2022
Q4 | $65.2M | Buy |
2,561,187
+288,272
| +13% | +$7.34M | 10% | 4 |
|
|
2022
Q3 | $54.6M | Sell |
2,272,915
-239,325
| -10% | -$5.75M | 11.51% | 2 |
|
|
2022
Q2 | $48.3M | Buy |
2,512,240
+579,440
| +30% | +$11.1M | 12.34% | 2 |
|
|
2022
Q1 | $33.6M | Buy |
1,932,800
+976,635
| +102% | +$17M | 10.9% | 3 |
|
|
2021
Q4 | $20.9M | Buy |
+956,165
| New | +$20.9M | 11.19% | 3 |
|